Obalon Therptcs (NASDAQ:OBLN) announced its earnings results on Friday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.12), Bloomberg Earnings reports. Obalon Therptcs had a negative return on equity of 108.07% and a negative net margin of 566.87%.

Shares of Obalon Therptcs (NASDAQ OBLN) traded up $0.59 during mid-day trading on Friday, hitting $8.96. 79,826 shares of the stock traded hands, compared to its average volume of 52,809. The company has a current ratio of 13.29, a quick ratio of 13.14 and a debt-to-equity ratio of 0.20.

Several equities research analysts have issued reports on OBLN shares. Northland Securities reaffirmed a “sell” rating and set a $6.00 target price on shares of Obalon Therptcs in a research note on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and set a $20.00 target price (down previously from $22.00) on shares of Obalon Therptcs in a research note on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Obalon Therptcs from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $15.25.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/03/obalon-therptcs-obln-issues-quarterly-earnings-results.html.

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Obalon Therptcs by 8.3% in the second quarter. Vanguard Group Inc. now owns 170,266 shares of the company’s stock valued at $1,687,000 after buying an additional 13,108 shares during the period. State Street Corp boosted its stake in shares of Obalon Therptcs by 66.1% in the second quarter. State Street Corp now owns 71,242 shares of the company’s stock valued at $705,000 after buying an additional 28,356 shares during the period. Finally, California State Teachers Retirement System boosted its stake in shares of Obalon Therptcs by 53.5% in the second quarter. California State Teachers Retirement System now owns 15,200 shares of the company’s stock valued at $151,000 after buying an additional 5,300 shares during the period. Institutional investors and hedge funds own 44.61% of the company’s stock.

About Obalon Therptcs

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Earnings History for Obalon Therptcs (NASDAQ:OBLN)

Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.